MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial

Journal:

Nature Communications

Published:

2026-03-19

DOI:

10.1038/s41467-026-70653-3

Affiliations:

5

Authors:

19

Go to article

Institutions	Authors	Share
University of Michigan Rogel Cancer Center, United States of America (USA)	11.000000 11.000000	0.58
H. Lee Moffitt Cancer Center & Research Institute, United States of America (USA)	3.000000	0.16
University of Chicago Comprehensive Cancer Center, United States of America (USA)	2.500000	0.13
Ascentage Pharma, United States of America (USA)	2.000000	0.11
Chan Zuckerberg Biohub Chicago, United States of America (USA)	0.500000	0.03

Interested in Oncology and Carcinogenesis?